Mut-KRAS detection was profoundly associated with the PDA outcomes, irrespective of the stage (hazard ratio (HR) = 2.42, 95% CI: 1.95–2.99 for OS and HR = 2.46, 95% CI: 2.01–3.00 for PFS) and in advanced stages (HR = 2.51, 95% CI: 1.90–3.31). This evidence concerns the gene KRAS and Patent ductus arteriosus.